Trial Profile
A Phase 2 Study of LY2523355 in Patients With Extensive-Stage Small-Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Litronesib (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Mar 2012 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 08 Sep 2011 Planned end date changed from 1 Oct 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.